Hidemi Aida (President, JCRO)

日本で抗がん剤初期の開発を
Make Innovation of Clinical Development in Japan Oncology Therapeutic Area.

It is well known that Japan is a rapidly aging society, which resulted cancer mortality is growing at a rapid pace. However, the availability of approved oncology therapies in Japan is limited as compared with US and European markets.
We, JCRO and KINKI University, Medical Oncology Departments, are focused on executing Phase I safety studies and special cohort studies in Japan, as an important part of Japan and global clinical development strategies. Our experienced investigators and clinical staff work together with innovative Genome-Biology Departments and Oncology Networks to enable highly targeted tumor typing and patient identification.
We look forward to discussing with you.
Sincerely,

Hidemi Aida (President, JCRO)

日本臨床研究オペレーションズ株式会社
JCRO代表:會田秀巳

Clinical
Research
Pharmacokinetics
Project
Management
Services
Traslational
Research
Consulting
Drug
Screening